# Pizarra — PT-pseudo_37d8ae9b27f1 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_37d8ae9b27f1
Task: 1

Encounter: Urology - outpatient on 18 Jan 2025.
Referrer: Dr. S. de Vries (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.053 ng/mL²
  - PSA velocity: 0.39 ng/mL/yr
  - Prior PSA: 4.7 ng/mL
  - Prostate volume: 90.82 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.46945655 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.05. Prostate volume 91 mL. csPCa 0.47.

Vitals: weight 76 kg, height 180 cm, BMI 23.5, BP 120/76 mmHg, HR 79 bpm. Smoking: Non-smoker.

Chief complaint: Clinical attention sought due to a previous prostate cancer diagnosis coupled with a recent serum PSA rise to 4.8 ng/mL.

History: At sixty-seven years of age, this widowed patient has a documented history of a prior positive biopsy confirming low-grade malignancy. Initial evaluation for an elevated PSA occurred in 2022. He experiences moderate lower urinary tract symptoms, scoring 16 on the IPSS questionnaire, dominated by nocturia and a diminished urinary stream that have not progressed recently. Occupational background includes work as a retired mechanical engineer. He resides independently. Lifestyle factors include being a Non-smoker, consuming six alcoholic units weekly, and participating in weekly swimming sessions. Past medical encounters involve standard audiology and vascular surgery visits for unrelated aging processes, with no other significant comorbidities or active medications reported. He explicitly denies bone discomfort, haematuria, or constitutional complaints.

Physical examination: Normal DRE: Symmetrically enlarged gland exhibiting a uniform, smooth consistency without focal hardening or asymmetry. Systemic inspection shows stable hemodynamic parameters, clear lung fields, and absence of peripheral edema or palpable lymph nodes.

Patient info: retired mechanical engineer; Widowed; Lives alone.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 6 units / week; exercise Swimming 1x/week; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Vascular surgery — varicose veins consult.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.64 +/- 0.19   (95% CI 0.25-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 7.1 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=4.8, age=67.0, psad=0.053, dre_ord=0.0, vol=90.82, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used discrete variables (PI-RADS=4.0, PSA=4.8, etc.) and could not weigh the clinical context, such as the prior positive biopsy result, the specific PSA velocity (0.39 ng/mL/yr), or the patient's moderate LUTS (IPSS 16), which are crucial for risk stratification.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a wide uncertainty interval (0.64 +/- 0.19), meaning the classifier is genuinely unable to distinguish between the two outcomes based on the limited input. The prior might be wrong because it failed to account for the critical context: a prior positive biopsy, which fundamentally changes the question from "does he have cancer?" to "is the existing disease stable or has it progressed?"

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior positive diagnosis
laboratory panel - full panel
previous notes - context regarding the prior positive diagnosis

GUIDELINE ANCHOR
The guideline criterion states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_37d8ae9b27f1", "radiology_report": "Subject: Multiparametric MRI Prostate | Radboudumc\nDate: 11 January 2021\n\nClinical context: Serum PSA currently measures 4.8 ng/mL, with a prior PI-RADS 4 classification.\n\nFINDINGS:\nGlandular dimensions total 90.82 mL. T2-weighted imaging isolates a discrete hypointense region within the left peripheral zone, spanning the mid-gland to the base, spanning roughly 14 by 9 mm. High b-value diffusion sequences show marked restriction, mirrored by hypointensity on the apparent diffusion coefficient map. Post-contrast dynamics highlight early, localized enhancement against the background peripheral tissue. The capsule remains intact without extraprostatic spread, seminal vesicle involvement, or nodal abnormalities.\n\nIMPRESSION:\nPI-RADS 4 lesion in the left peripheral zone.\nProstate volume 90.82 mL yielding a PSA density of 0.053 ng/mL/mL.\ncsPCa predicted probability 0.46945655"}
get_psa_trend
{"case_id": "PT-pseudo_37d8ae9b27f1", "psa_trend": [{"date": "Aug 2022", "val": 3.6}, {"date": "May 2023", "val": 1.2}, {"date": "Mar 2024", "val": 3.1}, {"date": "Jan 2025", "val": 4.8}]}
get_previous_notes
{"case_id": "PT-pseudo_37d8ae9b27f1", "previous_notes": [{"date": "23 May 2024", "author": "Dr. S. de Vries (GP)", "text": "28 July 2023 - Dr. S. de Vries (GP): Clinical review focused on the evolving PSA profile. The latest measurement registers at 4.1 ng/mL, reflecting a steady increase from the initial baseline. The clinical team will maintain standard surveillance protocols."}, {"date": "28 Jul 2023", "author": "Dr. S. de Vries (GP)", "text": "23 May 2024 - Dr. S. de Vries (GP): Laboratory analysis demonstrates a subsequent PSA increase to 4.7 ng/mL. Considering the documented history of a previously positive biopsy alongside this sustained elevation, a urology re-evaluation was initiated. The patient received notification regarding the outpatient appointment."}]}
get_lab_results
{"case_id": "PT-pseudo_37d8ae9b27f1", "laboratory_results": [{"name": "PSA", "val": "4.8 ng/mL", "date": "12 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.20 ng/mL", "date": "12 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "25%", "date": "12 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.8 g/dL", "date": "12 Dec 2024", "flag": ""}, {"name": "WBC", "val": "8.6 x10^9/L", "date": "12 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "210 x10^9/L", "date": "12 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "104 umol/L", "date": "12 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "12 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "13.2 nmol/L", "date": "12 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "50 U/L", "date": "12 Dec 2024", "flag": ""}, {"name": "LDH", "val": "193 U/L", "date": "12 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, but it is not required for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity: 0.39 ng/mL/yr (suggests progression).
- MRI report: PI-RADS 4 lesion in the left peripheral zone (identifies a suspicious lesion).
- Previous notes: Documented history of a previously positive biopsy and a recent PSA rise to 4.7 ng/mL.

AGAINST sampling this patient now:
- MRI report: Capsule remains intact without extraprostatic spread, seminal vesicle involvement, or nodal abnormalities.
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence points toward a need for further investigation due to the combination of a PI-RADS 4 lesion and a rising PSA velocity following a prior positive biopsy. This leans toward a recommendation for biopsy to characterize the existing disease.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the evidence points toward further investigation because the PSA velocity is 0.39 ng/mL/yr and the mpMRI shows a PI-RADS 4 lesion. The previous notes document the history of the prior positive biopsy and a recent PSA rise to 4.7 ng/mL, which suggests the existing disease is evolving. Since no documented ISUP grade or comparison against a named previous MRI exists to rule out stability, sampling is indicated to characterize the progression.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
